Treatment of Podocytopathies: Risky Business and Our Personal Journey.
作者信息
Sever Sanja, Reiser Jochen
机构信息
Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
The University of Texas Medical Branch at Galveston, Galveston, Texas.
出版信息
J Am Soc Nephrol. 2024 Nov 1;35(11):1600-1602. doi: 10.1681/ASN.0000000000000415. Epub 2024 May 15.
Abstract
摘要
相似文献
1
Treatment of Podocytopathies: Risky Business and Our Personal Journey.足细胞病的治疗：充满风险的事务与我们的个人历程
J Am Soc Nephrol. 2024 Nov 1;35(11):1600-1602. doi: 10.1681/ASN.0000000000000415. Epub 2024 May 15.
2
Potential targeting of urokinase-type plasminogen activator receptor-formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies.靶向尿激酶型纤溶酶原激活物受体-甲酰肽受体信号通路预防移植后原发性足细胞病复发的可能性
Am J Transplant. 2025 Jun 13. doi: 10.1016/j.ajt.2025.06.010.
3
Exploring Journey Maps as Products From Qualitative Research: Application Through Food Insecure Veterans' Experiences.探索作为定性研究成果的旅程地图：通过粮食不安全退伍军人的经历进行应用
Qual Health Res. 2024 Oct 4:10497323241274333. doi: 10.1177/10497323241274333.
4
A Machine Learning Approach Using Topic Modeling to Identify and Assess Experiences of Patients With Colorectal Cancer: Explorative Study.一种使用主题建模的机器学习方法来识别和评估结直肠癌患者的经历：探索性研究。
JMIR Cancer. 2025 Jan 27;11:e58834. doi: 10.2196/58834.
5
A Transformative Leadership Journey: Experiences of Graduates of the American Physical Therapy Association Fellowship in Education Leadership.变革型领导力之旅：美国物理治疗协会教育领导力研究员的经历。
J Phys Ther Educ. 2023 Mar 1;37(1):60-69. doi: 10.1097/JTE.0000000000000255. Epub 2022 Oct 25.
6
The Significance of Hematuria in Podocytopathies.血尿在 podocytopathies 中的意义。
Clin J Am Soc Nephrol. 2024 Jan 1;19(1):56-66. doi: 10.2215/CJN.0000000000000309. Epub 2023 Sep 21.
7
Novel method to plan and design services. Using software to optimise the head and neck cancer patient's commute to hospital.规划和设计服务的新方法。使用软件优化头颈部癌症患者前往医院的通勤。
Br J Oral Maxillofac Surg. 2024 Feb;62(2):150-156. doi: 10.1016/j.bjoms.2023.10.016. Epub 2023 Nov 3.
8
Leading Change at Berkeley Public Health: Building the Anti-racist Community for Justice and Social Transformative Change.在伯克利公共卫生领域引领变革：建立反种族主义社区，以实现正义和社会变革。
Prev Chronic Dis. 2023 Jun 8;20:E48. doi: 10.5888/pcd20.220370.
9
Staying afloat on a realm of shifting sands: carers navigating palliative care in their rural settings.在变幻莫测的领域中保持不沉：农村地区的护理人员在姑息治疗中艰难前行。
Rural Remote Health. 2025 Jul;25(3):9343. doi: 10.22605/RRH9343. Epub 2025 Jul 8.
10
Community Engagement in Long Covid Research: Process, Evaluation and Recommendations From the Long COVID and Episodic Disability Study.社区参与长新冠研究：来自长新冠与发作性残疾研究的过程、评估及建议
Health Expect. 2025 Aug;28(4):e70365. doi: 10.1111/hex.70365.
本文引用的文献
1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.斯巴森坦治疗 IgA 肾病患者：一项随机、双盲、活性对照临床试验的预先指定中期分析。
Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
2
Inaxaplin for Proteinuric Kidney Disease in Persons with Two Variants.Inaxaplin 用于伴有两种变异的蛋白尿性肾病患者。
N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396.
3
FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?达格列净获美国食品药品监督管理局批准用于慢性肾病：一项非凡成就？
Lancet. 2021 Jul 24;398(10297):283-284. doi: 10.1016/S0140-6736(21)01242-3. Epub 2021 Jun 4.
4
GLP-1 Receptor Agonists in Diabetic Kidney Disease.糖尿病肾病中的胰高血糖素样肽-1受体激动剂
Clin J Am Soc Nephrol. 2021 Oct;16(10):1578-1580. doi: 10.2215/CJN.18771220. Epub 2021 Apr 13.
5
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.蛋白尿减少作为 IgA 肾病试验的替代终点。
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.
6
Risk Alleles are Associated with More Severe Arteriosclerosis in Renal Resistance Vessels with Aging and Hypertension.风险等位基因与衰老和高血压导致的肾阻力血管中更严重的动脉硬化有关。
Kidney Int Rep. 2016 May;1(1):10-23. doi: 10.1016/j.ekir.2016.03.002. Epub 2016 Apr 20.
7
Exploring the genetic basis of early-onset chronic kidney disease.探索早发性慢性肾脏病的遗传基础。
Nat Rev Nephrol. 2016 Mar;12(3):133-46. doi: 10.1038/nrneph.2015.205. Epub 2016 Jan 11.
8
Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.肌动蛋白依赖性发动蛋白寡聚化的药理学靶向改善了多种动物模型中的慢性肾病。
Nat Med. 2015 Jun;21(6):601-9. doi: 10.1038/nm.3843. Epub 2015 May 11.
9
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.APOL1 基因变异与局灶节段性肾小球硬化和 HIV 相关性肾病。
J Am Soc Nephrol. 2011 Nov;22(11):2129-37. doi: 10.1681/ASN.2011040388. Epub 2011 Oct 13.
10
Modification of kidney barrier function by the urokinase receptor.尿激酶受体对肾脏屏障功能的调节
Nat Med. 2008 Jan;14(1):55-63. doi: 10.1038/nm1696. Epub 2007 Dec 16.
Zotero 插件